Industry news that matters to you.  Learn more

Smell And Eye Tests Show Potential To Detect Alzheimer’s Early

A decreased ability to identify odors might indicate the development of cognitive impairment and Alzheimer’s disease, while examinations of the eye could indicate the build-up of beta-amyloid, a protein associated with Alzheimer’s, in the brain, according to the results of four research trials reported recently at the Alzheimer’s Association International Conference® 2014 (AAIC® 2014) in Copenhagen.

Piramal Imaging Announces EU Approval of NeuraCeq (florbetaben 18F) for PET Imaging of Beta-Amyloid Neuritic Plaque Density in the Brain

Piramal Imaging recently announced that NeuraCeq™ has received marketing authorization from the European Commission.

Probiodrug and VU University Medical Center in Amsterdam to Collaborate on the Development of Alzheimer’s Disease Biomarker Assays

Probiodrug AG (Probiodrug), together with the VU University Medical Center (VUmc) Alzheimer Center in Amsterdam, have entered into a collaboration to assess several newly developed molecular biomarker assays for their diagnostic, pharmacodynamic, and therapeutic potential. In this collaboration, cerebrospinal fluid (CSF) samples from well-characterized Alzheimer’s disease (AD) patients at different stages of disease will be analyzed in comparison with CSF from age-matched control samples. The assays are designed to detect the presence and concentration of pyroglutamated amyloid beta (pGlu Abeta), a highly toxic peptide produced by the enzyme glutamaminyl cyclase (QC). PGlu Abeta has been correlated with cognitive decline in individuals with AD, and this collaboration seeks to correlate CSF concentrations of pGlu Abeta with AD disease stage.

Shorter Sleep Duration and Poorer Sleep Quality Linked to Alzheimer’s Disease Biomarker

Poor sleep quality may impact Alzheimer’s disease onset and progression. This is according to a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health who examined the association between sleep variables and a biomarker for Alzheimer’s disease in older adults. The researchers found that reports of shorter sleep duration and poorer sleep quality were associated with a greater β-Amyloid burden, a hallmark of the disease. The results are featured online in the October issue of JAMA Neurology.

Inventages Portfolio Company, Cognoptix, Demonstrates the Ability to Accurately Identify Alzheimer’s Disease

Inventages announces that one of its portfolio companies, Cognoptix, has demonstrated unprecedented accuracy in detecting Alzheimer’s disease. A multi-site clinical trial of the SAPPHIRE II eye test showed a sensitivity of 85% and a specificity of 95% in differentiating Alzheimer’s disease patients from healthy volunteers.